Wake Research Associates LLC

1. Incyte Corporation $495,382 83 payments
2. Regeneron Pharmaceuticals, Inc. $271,586 19 payments
3. Pfizer Inc. $265,201 59 payments
4. Allergan Inc. $151,573 45 payments
5. Sunovion Pharmaceuticals Inc. $97,844 8 payments
6. LEO Pharma AS $51,428 9 payments
7. Takeda Pharmaceuticals U.S.A., Inc. $49,793 7 payments
8. AMAG Pharmaceuticals, Inc. $49,441 6 payments
9. Jazz Pharmaceuticals Inc. $18,000 1 payment
10. Adare Pharmaceuticals, Inc. $5,576 4 payments

1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $271,586 19 payments
2. TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $269,282 31 payments
3. A Phase 3B4 Multicenter Randomized Assessor Blinded Vehicle and Active Topical Corticosteroid and Calcineurin Inhibitor Controlled Parallel Group Study of the Efficacy Safety and Local Tolerability of Crisaborole Ointment 2 in Pediatric and Adult Subjects Ages 2 Years and Older With Mild to Moderate Atopic Dermatitis $190,272 30 payments
4. TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $141,582 7 payments
5. Dasotraline Binge Eating Disorder Extension Study $97,844 8 payments
6. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $57,521 2 payments
7. Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo $51,703 14 payments
8. Prasterone DHEA for the Treatment of Hypoactive Sexual Desire Disorder HSDD - Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone $49,441 6 payments
9. A Phase 2A Randomized Doubleblind Placebocontrolled Doseranging Parallel Group Study to Evaluate Safety Tolerability and Pharmacodynamics of Pf05221304 Administered Daily for 16Weeks to Adult Subjects With Nonalcoholic Fatty Liver Disease $32,875 14 payments
10. Entyvio (Vedolizumab) Long-Term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis Or Crohn's Disease $32,659 3 payments

1. Other $16,306 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.